News Former CEO wins bidding war for 23andMe, beating Regeneron 23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.
News New auction for 23andMe sought with $305m bid from ex-CEO A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron.
News 23andMe founder isn't giving up her bid to regain control 23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.
News ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.
News GSK claims first approval for Nucala in COPD GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
